CAJ | 학술논문

目的:探讨多药耐药基因(MDR1)多态性对乳腺癌紫杉联合蒽环类(TA)化疗疗效的预测价值.方法:利用PCR-RFLP技术对142例乳腺癌患者进行MDRl基因变异检测,观察其多态性分布;并对其中接受TA方案的具有完整疗效评价资料的63例新辅助化疗患者,开展MDR1 12外显子C1236T、21外显子G2677T/A和26外显子C3435T基因多态性与化疗疗效的相关分析.结果:C1236T、G2677T/A和C3435T在142例中国汉族乳腺癌女性人群中的变异频率分别为70.7%、55.0%和46.5%.其中,3435TT基因型在63例新辅助化疗患者中表现出与TA疗效的关联,其有效率(23.1%)显著低于携带C等位基因的患者(73.5%;X2=9.125,P=0.003).3个位点多态之间存在连锁不均衡性,携带3435C-2677G单体型的患者,化疗有效率(72.1%)高于其他单体型携带者(40.0%;X2=5.962,P=0.015),携带3435T-2677T或3435T-1236T单体型者,化疗有效率(54.3%或54.9%)低于对应的其他单体型携带者(82.4%和91.7%;X2=4.128和X2=4.118,P均为0.042);携带有3435T-2677T-1236T单体型者,化疗有效率(54.3%)低于其他单体型携带者(82.4%;X2=4.128,P=0.042).结论:MDR1 C3435T基因型及其与G2677T/A和(或)C1236T的单体型检测对于乳腺癌TA联合化疗疗效的预测具有重要参考价值.
목적:탐토다약내약기인(MDR1)다태성대유선암자삼연합은배류(TA)화료료효적예측개치.방법:이용PCR-RFLP기술대142례유선암환자진행MDRl기인변이검측,관찰기다태성분포;병대기중접수TA방안적구유완정료효평개자료적63례신보조화료환자,개전MDR1 12외현자C1236T、21외현자G2677T/A화26외현자C3435T기인다태성여화료료효적상관분석.결과:C1236T、G2677T/A화C3435T재142례중국한족유선암녀성인군중적변이빈솔분별위70.7%、55.0%화46.5%.기중,3435TT기인형재63례신보조화료환자중표현출여TA료효적관련,기유효솔(23.1%)현저저우휴대C등위기인적환자(73.5%;X2=9.125,P=0.003).3개위점다태지간존재련쇄불균형성,휴대3435C-2677G단체형적환자,화료유효솔(72.1%)고우기타단체형휴대자(40.0%;X2=5.962,P=0.015),휴대3435T-2677T혹3435T-1236T단체형자,화료유효솔(54.3%혹54.9%)저우대응적기타단체형휴대자(82.4%화91.7%;X2=4.128화X2=4.118,P균위0.042);휴대유3435T-2677T-1236T단체형자,화료유효솔(54.3%)저우기타단체형휴대자(82.4%;X2=4.128,P=0.042).결론:MDR1 C3435T기인형급기여G2677T/A화(혹)C1236T적단체형검측대우유선암TA연합화료료효적예측구유중요삼고개치.